Advertisement
Screener

Standard BioTools Inc. (LAB) Cash

2.8 / 5 stars · 68/120 Roast Me

Standard BioTools Inc. Cash

Standard BioTools Inc. (LAB) had Cash of $17.68 million as of 2018-12-31, per its 10-K filed 2019-03-18.

Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments

us-gaap:Cash · last filed 2019-03-18

  • 2018-12-31: Cash $17.68M.
  • 2018-09-30: Cash $13.76M.
  • 2017-12-31: Cash $20.13M.
  • 2016-12-31: Cash $13.98M.
Period endCash
2018-12-31$17.68M
10-K · filed 2019-03-18
2018-09-30$13.76M
10-Q · filed 2018-11-06
2017-12-31$20.13M
10-K · filed 2019-03-18
2016-12-31$13.98M
10-K · filed 2018-03-08
2016-06-30$15.64M
10-Q · filed 2016-08-09
2016-03-31$17.48M
10-Q · filed 2016-05-09
2015-12-31$17.89M
10-K · filed 2017-03-03
2015-09-30$17.98M
10-Q · filed 2015-11-09
2015-06-30$13.02M
10-Q · filed 2015-08-10
2015-03-31$21.08M
10-Q · filed 2015-05-11
2014-12-31$23.49M
10-K · filed 2016-02-29
2014-09-30$20.38M
10-Q · filed 2014-11-06
2014-06-30$26.29M
10-Q · filed 2014-08-04
2014-03-31$23.53M
10-Q · filed 2014-05-12
2013-12-31$17.71M
10-K · filed 2015-02-26
2013-09-30$14.30M
10-Q · filed 2013-11-07
2013-06-30$14.98M
10-Q · filed 2013-08-07
2013-03-31$60.29M
10-Q · filed 2013-05-09
2012-12-31$57.08M
10-K · filed 2014-03-12
2012-09-30$62.77M
10-Q · filed 2012-11-09
2012-06-30$9.84M
10-Q · filed 2012-08-14
2011-12-31$11.75M
10-K · filed 2013-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01